Please login to the form below

Eliquis

This page shows the latest Eliquis news and features for those working in and with pharma, biotech and healthcare.

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

The positive quarterly results build on BMS’ key patent challenge victory on Wednesday for its blood thinner Eliquis (apixaban). ... Eliquis was the second biggest seller in the second quarter, bringing in $4.8bn.

Latest news

Celgene drugs drive BMS to a buoyant Q4, but Opdivo stalls

BMS’ well-established anticoagulant Eliquis (apixaban) had another strong quarter with a 19% rise to just over $2bn, while multiple myeloma drug Empliciti (elotuzumab) grew by more than a third to
Vyndaqel a bright spot as Pfizer comes under pressure

ago. Meanwhile, vaccine blockbuster Prevnar also continued its slowdown, but still brought in $1.58bn in the quarter, and anticoagulant Eliquis (apixaban) continued its strong growth with a 21% gain to
FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis

Sets stage for lower-cost competition to big-selling drug. The FDA has approved the first two generics of Pfizer and Bristol-Myers Squibb’s blockbuster anticoagulant drug Eliquis, from Micro ... The two companies have been actively challenging attempts
BMS’ Opdivo stalls in Q3, but overall figures still top expectations

Anticoagulant Eliquis (apixaban) did better than predicted with a 22% increase to $1.93bn, and there were also solid gains for arthritis and psoriasis therapy Orencia (abatacept) – up 14% to $767m –
The business case for patient engagement

The results, as depicted in the chart, suggest that patients are equally likely to promote Xarelto and Eliquis, despite the latter earning more confidence. ... Are Lixiana users missing the confidence that Xarelto and Eliquis users have, and is this what

More from news
Approximately 15 fully matching, plus 78 partially matching documents found.

Latest Intelligence

The handover: Pfizer reshapes itself for a new era

Innovative health revenue increased 4% to $8.47bn, lifted by sales of blood thinner Eliquis and breast cancer drug Ibrance outside the US, among others.
The good, the bad and the ugly

This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.
Modern anticoagulants threaten status quo

Apixaban. Bristol-Myers Squibb and Pfizer are developing apixaban (Eliquis), which is an oral, twice-daily, selective factor Xa inhibitor.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

PPD expands global product department with new therapeutic area heads

Puneet Mohan (left) comes to PPD from Bristol-Myers Squibb, where he most recently served as executive director of global clinical development and global clinical leader for Eliquis (apixaban).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....